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Background~Aims: Therapeutic vaccination is a new 
approach to treat patients with chronic hepatitis B vi- 
rus infection. We have used the woodchuck model to 
examine the efficacy and safety of this approach. 
Methods: Seven woodchucks chronically infected with 
woodchuck hepatitis virus were immunized with sur- 
face antigen from this virus, purified from plasma, in 
conjunction with a peptide named FIS (encompassing 
amino acids 106-118: FISEAIIHVLHSR from sperm 
whale myoglobin), which is recognized by T helper 
lymphocytes. As controls, two woodchucks chronic- 
ally infected with woodchuck hepatitis virus were im- 
munized: one with FIS only and the other with surface 
antigen only. 
Results: Co-immunization with surface antigen and 
FIS, but not with FIS or surface antigen alone, in- 
duced anti-surface antibodies in 7/7 immunized wood- 
chucks. In the two woodchucks in which the highest 
titer of anti-surface antibody was elicited, severe liver 
damage was observed: one died of fulminant hepatitis 
and the other became seriously iH with hepatic injury 
and had to be sacrificed. 
Conclusions: Co-immunization of chronically infected 
woodchucks with surface antigen and a peptide recog- 
nized by T helper cells produces a good anti-sm'face 
antibody response. However, this strategy needs to be 
optimized before its implementation in humans. Al- 
though our experiments are not strictly comparable 
to vaccination of chronically hepatitis B virus-infected 
patients with recombinant or plasma-derived vaccines, 
we believe that precautions hould be taken to avoid 
the risk of severe liver injury when immunizing hepa- 
titis B virus carriers. 
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C HRONIC hepatitis B virus (HBV) infection is char- acterized by a poor humoral and cellular immune 
response against HBV antigens. It has been suggested 
that this lack of response may be associated with a 
reduced T helper response to antigens of HBV (1-3). 
At least three groups have attempted to vaccinate 
chronically HBV-infected patients to induce antibodies 
against HBV surface antigen (HBsAg) in order to elim- 
inate the chronic infection. The vaccines used were 
plasma-derived HBsAg (4,5) or recombinant HBsAg 
containing preS2 sequences (6). In the study by Dien- 
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stag et al. (4) there was no evidence that HBV vaccine 
was effective in eliminating HBV, despite one of 10 
HBV "e" antigen-positive carriers losing this antigen 
and despite decreased ALT activity in half the partici- 
pants. By contrast, Pol et al. (6) reported that vacci- 
nation of chronic carriers with HBsAg containing the 
preS2 region had the effect of lowering HBV repli- 
cation (in 28.6% of patients) and decreasing the HBV 
DNA to undetectable levels (in 21.4% of patients). Wen 
et al. (5) immunized patients with chronic hepatitis B 
infection, with hepatitis B vaccine complexed to hu- 
man hepatitis B immunoglobulin. They found that 9/ 
14 patients became negative for serum HBV DNA 
after three immunizations with the complex. All 
groups reported that vaccination appeared to be safe, 
with no side-effects, and no anti-HBs antibodies were 
detected after immunization. 
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Our laboratory has made attempts to develop strat- 
egies to induce humoral (7-9) and cytotoxic (10,11) re- 
sponses using synthetic peptides. We have shown (9) 
that SJL/J mice, normally non-responders to HBsAg, 
can be rendered responders by joint immunization with 
HBsAg and a T helper cell determinant peptide (TDh) 
encompassing residues 106-118 from sperm whale 
myoglobin (from now on designated FIS). This result 
encouraged us to explore this strategy of joint immu- 
nization in the woodchuck model to attempt to elimin- 
ate woodchuck hepatitis virus (WHV) chronic infec- 
tion as a preliminary step to its implementation as 
therapeutic vaccination in HBV chronic carriers. 
Woodchucks, when infected with WHV, develop 
chronic hepatitis that closely resembles chronic HBV 
infection in humans. Also, infection with WHV, like 
HBV, carries a significant risk of hepatocellular carci- 
noma (12,13). Both viruses belong to the hepadnavirus 
family with a very similar genome organization coding 
for proteins of high homology (14). Viremia of WHV 
in the woodchuck reaches high levels (10 9 particles/ml) 
similar to those observed in HBV-infected patients 
(15,16). 
In this paper we demonstrate hat immunization of 
chronically infected woodchucks with WHV surface 
antigen (WHsAg) and FIS can induce anti-WHs anti- 
bodies and in some instances may be associated with 
liver injury. 
Materials and Methods 
Animals 
A total of 10 woodchucks were used in the present 
study. Four 4-5-year-old woodchucks (310, 90-5, 449 
and 67) chronically infected with WHV (WHsAg(+), 
WHV DNA(+), anti-WHs(-)) born in captivity and 
housed at the animal facilities at the University of Es- 
sen (Germany), were used in the first experiment. In a 
second experiment we used one non-infected (1D) and 
five chronically infected (1D2I, 845, 848, 079 and 342) 
woodchucks 2-3 years old; they were born in the wild 
and were purchased from North Eastern Wildlife 
(Ithaca, NY, USA). All animals were treated according 
to the guidelines from our institution (CIFA, Pam- 
plona, Spain). 
Peptide synthesis 
Peptides were synthesized by the solid-phase method of 
Merrifield (17) using the Fmoc alternative (18). Peptide 
HBs120-134 (MQWNSTAFHQTLQDP) encompassing 
residues 120-134 from HBsAg was synthesized using a 
multiple solid phase peptide synthesizer (19). Peptide 
FIS (FISEAIIHVLHSR) encompassing residues 106- 
118 from sperm whale myoglobin was done manually 
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and the ninhydrin test of Kaiser et al. (20) used to 
monitor every step. FIS was purified by high perform- 
ance liquid chromatography (HPLC) on a reverse 
phase C 18 column. 
Purification of WHsAg 
WHsAg was purified according to Gerin et al. (21) with 
minor modifications. Basically, the antigen was isolated 
from the serum of a chronically WHV-infected wood- 
chuck by zonal centrifugation on a sucrose gradient fol- 
lowed by isopicnic entrifugation i a gradient of CsC1. 
The peak of WHsAg was contained in fractions with a 
density of 1.19-1.22 g/ml and was identified by SDS 
polyacrylamide gel electrophoresis and silver staining. 
Those fractions containing the antigen were pooled and 
dialyzed against 20 mM Tris pH 7.4, 140 mM NaC1, 1 
mM EDTA, and quantified using the kit Bio-Rad pro- 
tein assay (Bio-Rad, Richmond, CA, USA). 
Preparation of antibodies to WHsAg 
Anti-WHs antibodies were induced by intradermal im- 
munization of New Zealand white male rabbits with 100 
pg of WHsAg emulsified in complete Freund's adjuvant. 
Rabbits were boosted subcutaneously with the same 
dose of antigen in incomplete Freund's adjuvant at day 
30 after the first immunization. Immunoglobulins con- 
taining anti-WHs antibodies were isolated from the sera 
at day 45 by chromatography ona column of protein A 
superose HR 10/2 (Pharmacia, Uppsala, Sweden). The 
column was equilibrated by washing with 8 ml of dis- 
tilled water followed by 3.2 ml of 0.1 M Tris pH 8.0. One 
ml of serum, with an anti-WHs antibody titer of 1:10 500 
was centrifuged at 10 000 g for 10 min and the super- 
natant passed through a 0.22/zm filter (Micron Separ- 
ations Inc., Westboro, MA, USA). The filtrate (0.9 ml) 
was mixed with 0.1 ml of 1 M Tris pH 8.0 and injected 
into the column. The column was then washed with 16 
ml of 0.1 M Tris pH 8.0 at a flow rate of 0.5 ml/min for 4 
min and at 2 ml/min for 7 min, followed by another wash 
with 16 ml of 0.01 M Tris pH 8.0 at 2 ml/min. The IgGs 
were eluted with 16 ml of 0.1 M glycine-HC1 pH 3.0 (2 
ml at 0.5 ml/min followed by 14 ml at 2 ml/min). The 
peak of IgGs was collected, quickly neutralized with 1 
M Tris pH 8.0 and dialyzed against 0.1 M carbonate/bi- 
carbonate buffer pH 9.8. This afforded 7.7 mg of IgG at 
a concentration of 3.8 mg/ml and was concentrated to
8.5 mg/ml by centrifugation at10 000 g for 60 min using 
a centrifuge tube with a 10 K filter (Filtron Technology 
Corp., Northborough, MA, USA). 
Labeling of anti- WHs antibodies with peroxidase 
Labeling of anti-WHs antibodies was carried out by 
reacting IgGs in 0.1 M carbonate/bicarbonate buffer 
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pH 9.8, with a 5 molar excess of activated horseradish 
peroxidase (HRPO) according to manufacturer's in- 
structions (Boehringer Mannheim GmbH, Mannheim, 
Germany). Briefly, 300/4 of IgGs (8.5 mg/ml) were re- 
acted with 100/A of HRPO (16 mg/ml) for 2 h at 25°C 
and 12 h at 4°C. The reaction was stopped with 40/zl 
of 2 M triethanolamine solution (pH 8.0). Freshly 
made 0.2 M solution of sodium borohydrate (50 /4) 
was added and incubated for 30 min at 4°C. Then, 25 
/d of 2 M triethanolamine (pH 8.0) was added and 
incubated for a further 2 h. To stabilize the conjugate, 
10 /tl of 1 M glycine-NaOH solution pH 7.0 were 
added and dialyzed against saline phosphate pH 7.4 
containing 0.01 M glycine. After 16 h dialysis at 4°C, 
bovine serum albumin and Kathon CG (Rohm & 
Haas, Frankfurt/Main, Germany) were added to a fi- 
nal concentration of 10 mg/ml and 1 mg/ml, respec- 
tively. The final solution was kept in small aliquots, 
which were quickly frozen in liquid nitrogen and stored 
at -80°C for further use. 
Detection of  WHsAg & sera 
Wells from ELISA plates (Nunc Maxisorp, Roskilde, 
Denmark) were coated at 4°C overnight, with 50/d of 
1/1500 dilution of a stock serum of anti-WHs anti- 
bodies (3.8 mg/ml) in 0.1 M sodium carbonate pH 
10.5. After three washes with phosphate buffered saline 
containing 1% Tween 20 (PBST), the plates were incu- 
bated at 37°C for 1 h with PBSMT (PBST with 1% 
powdered milk) supplemented with 2% serum from 
woodchucks negative for markers of WHV infection. 
Following removal of this solution, 50/zl per well of 
serum dilutions in PBSMT were added and incubated 
at 37°C for 1 h. The wells were then washed three times 
with PBST, and incubated at 37°C for another hour 
with 50/A of a 1/1000 dilution of a 4.25 mg/ml stock 
solution of anti-WHs-HRPO in PBSMT, contain- 
ing 2% serum from a non-infected woodchuck 
(PBSMTW). This PBSMTW dilution had been pre- 
viously incubated for 1 h at 37°C to block antibodies 
against woodchuck serum proteins that might con- 
taminate the anti-WHs-HRPO preparation. After 
three washes with PBST, the color reaction was started 
by adding 100/d/well of a solution prepared by mixing 
10 ml 0.6% acetic acid (pH 4.7), 7.5/tl of 33% (w/v) 
hydrogen peroxide and 100/zl of 45 mM aqueous olu- 
tion of ABTS (2,2'-azino-bis (3-ethylbenzothiazoline- 
6-sulfonic acid). After 1 h, the OD at 405 nm was read. 
The amount of WHsAg in the sera (in pg/ml) was cal- 
culated by comparison against a standard curve ob- 
tained with known concentrations of WHsAg. In this 
assay, the determined standard eviations of the means 
were less than 10% (range 8-11%). 
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Immunization experiments 
Woodchucks (non-infected, as well as chronically in- 
fected with WHV) were immunized intradermally in 10 
different sites with 100/zl of immunization mixture per 
site. This immunization mixture was obtained by 
sonication of 0.5 ml of complete Freund's adjuvant, 
and 0.5 ml of 0.1 M sodium carbonate solution con- 
taining the TDh peptide and WHsAg isolated from the 
serum of a chronically infected woodchuck (see above). 
In a first experiment (Fig. 1), this emulsion was made 
with 600/2g of either FIS or nBs120_134, and 200/.tg or 
100/tg of WHsAg. In the following experiments (Fig. 
2) we used 200/tg of FIS and 50/zg of WHsAg. As 
control, two chronically infected animals were immun- 
ized respectively with FIS (200/zg) or with WHsAg (50 
/tg) only. Three booster injections with the same dose 
of antigens, in incomplete Freund's adjuvant, were 
given as indicated in Fig. 1 and 2. The first boost was 
given by subcutaneous injection and the remaining two 
by intramuscular injection. Woodchucks were bled 
from the femoral vein under sedation (25 mg/kg Imal- 
gene 500 (Rhone M6rieux, Lyon, France) and 2.5 mg/ 
kg Rompun (Bayer, Leverkusen, Germany)). Blood 
was allowed to clot at 37°C for 1 h, and sera were col- 
lected by centrifugation at 8000 g for 2 min and stored 
at -80°C for further use. 
1L-2 production assay 
Peripheral blood mononuclear cells (PBMC) were iso- 
lated from fresh EDTA-treated blood (4-5 ml) by Fic- 
oll-Hypaque (Nycomed Pharma AS, Oslo, Norway), 
washed three times, counted, and resuspended at 
4x 106 cells/ml in complete medium (RPMI-1640, 10% 
fetal calf serum, 100 U/ml penicillin, 100/~g/ml strepto- 
mycin and 2x10 -5 M fl-mercaptoethanol). If neces- 
sary, remaining red cells were lysed by incubation at 
room temperature for 5 min with 5 ml of erythrocyte 
lysis buffer (0.15 M ammonium chloride, 1 mM potas- 
sium bicarbonate, 0.1 mM EDTA (pH 7.2-7.4) ). 
Then, 15 ml of 0.9% NaCI aqueous olution was added 
to the incubation mixture and washed twice with the 
same solution. PBMC were taken after the third 
(woodchuck 848) or fourth immunization (wood- 
chucks 1D, 1D2I and 845). 
Cells (4x 105 cells/well in 0.1 ml) were added in trip- 
licate to a 96-well flat-bottomed plate containing 100 
/d of antigen solution and cultured at 37°C and 5% 
CO2 for 24 h (WHsAg was tested at 2, 10 and 100/tg/ 
ml, and FIS was tested at 10 and 50/Lg/ml). Concanav- 
alin A (20/~g/ml) was used as a positive control. Super- 
natants (50/4) were removed and tested for their IL-2 
content using the CTL-L bioassay as already described 
(22). Briefly, CTL-L cells were resuspended in RPMI- 
1640 with 10% fetal calf serum, antibiotics and 2-mer- 
captoethanol (5x10 -s M), and were plated (8×10 3
cells/well) in a 96-well fiat-bottomed plate with the 
supernatant to be assayed (25% v/v). After 24 h of cul- 
ture, the stimulated CTL-L cells were pulsed with 1 
/tCi/well of [3H]thymidine for 18 h and thymidine in- 
corporation was determined by liquid scintillation. Re- 
suits are expressed as stimulation index (SI), which is 
the ratio of the mean counts, min -~ incorporated in 
the presence of antigen to the mean counts, min- 1 ob- 
tained in the absence of antigen. 
Determination of anti-WHs and anti-peptide antibodies 
Antibodies were titrated by ELISA. Microtiter wells 
were coated by overnight incubation at 4°C with either 
50/tl of peptide solutions (20 pg/ml) or WHsAg (2/~g/ 
ml) in 0.1 M sodium carbonate buffer. Wells were then 
washed three times with a solution of PBST. To block 
non-specific antibody binding, the wells were incubated 
at room temperature for 1 h with 400 ¢tl/well of the 
above buffer, but containing 1% powdered milk and 
0.1% Tween 20 (PBSMT). After removing the PBSMT, 
50 /d of different serum dilutions in PBSMT were 
added and incubated at 37°C for 1 h. Wells were 
washed three times with PBST and then incubated at 
37°C for 1 h with 50 ¢tl of a solution in PBSMT of 
Protein A-peroxidase (1/zg/ml) (Prot A-HRPO, Sigma 
Chemical Co., St. Louis, MO, USA). To measure anti- 
WHs antibody titers in rabbit sera, the plates were in- 
cubated with 50 ¢d/well of a 1:12 800 dilution of anti- 
rabbit IgG labeled with HRPO (Amersham Interna- 
tional plc., Amersham, UK). After washing three times 
with PBST, the color reaction was carried out as de- 
scribed for the detection of WHsAg in the sera. Anti- 
body titers correspond to the highest serum dilution to 
yield three times the absorbance of a negative serum 
and were expressed as the reciprocal value of the di- 
lution. In the determination of anti-WHs antibody tit- 
ers, the determined standard eviations of the means 
were less than 18% (range 13-22%). In the determi- 
nation of anti-FIS antibody titers, the determined 
standard eviations of the means were less than 13% 
(range 12-14%). 
Levels of ~/-GTP and bilirubin 
y-GTP and bilirubin were measured as previously re- 
ported (23,24) but using the autoanalyzer Hitachi 717 
(Hitachi Ltd., Tokyo, Japan). 
Determination of WHV DNA levels 
By dot blot. The level of WHV DNA in the sera was 
measured by dot blot hybridization, using a plasmid 
(pBr325WHS) containing the entire WHV genome 
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(WC8 clone) as the DNA probe (American Type Cul- 
ture Collection). Dot blot and DNA probe labeling 
were performed following standard protocols (25). 
Basically, the sera were diluted several times in H20 
and 5/tl from the undiluted sera, or from each dilution, 
was spotted onto a positively charged nylon membrane 
(Boehringer Mannheim GmbH, Mannheim, Ger- 
many). Denaturation of WHV DNA was performed 
by treating the membrane with a solution containing 1 
M NaC1 and 0.1 M NaOH and then with another solu- 
tion composed of 1 M NaC1 and 0.1 M Tris-HC1 (pH 
7.5). Finally, the DNA was fixed to the membrane by 
UV crosslinking. Before hybridization, the membrane 
was incubated at 42°C with a hybridization solution 
composed of formamide (50%) (v/v), 5XSSC (0.75 M 
NaCI, 0.085 M Na-citrate, pH 7.0); N-lauroylsarcosine 
(0.1%) (w/v), SDS (0.02%) (w/v), sperm salmon DNA 
(0.5 mg/ml) and blocking reagent (5%) (Boehringer 
Mannheim GmbH, Mannheim, Germany). After 4 h, 
50 ng/membrane of labeled DNA probe were added 
to the hybridization solution and the membrane was 
reincubated for another 15 h at 42°C. The DNA probe 
was previously labeled with digoxigenin (Dig-DNA 
probe) by random primer labeling. To eliminate non- 
specific binding of Dig-DNA probe, the membrane was 
washed 2x15 min at 42°C with 2xSSC, SDS (0.1%) 
(w/v) and 2x15 min at 68°C with 0.1xSSC, SDS 
(0.1%) (w/v). After hybridization, the membrane was 
blocked with a solution composed of 0.15 M NaC1, 
0.1 M Tris (pH 7.5) and 0.5% blocking reagent from 
Boehringer Mannheim. The hybrids formed by WHV 
DNA and Dig-DNA probe were detected according to 
Bronstein (26) with minor modifications, using an anti- 
digoxigenin antibody conjugated to alkaline phospha- 
tase (Boehringer Mannheim GmbH, Mannheim, Ger- 
many) and Lumigen PPD (Lumigen, Inc., Detroit, MI, 
USA) as chemiluminescent substrate. The light emitted 
by decomposition of the substrate was documented on 
a Kodak X-OMAT film. The density of the spot was 
measured by Scan Analysis (Apple Computer Inc., Cu- 
pertino, CA, USA). The amount of WHV DNA in 
each spot was expressed in ng/ml by comparison 
against a calibration curve obtained using solutions of 
WHV DNA of known concentration. In the determi- 
nation of WHV DNA levels, the determined standard 
deviations of the means were less than 18%. 
By competitive PCR. Construction of the competitive 
template: Plasmid pBR325WHS containing the WHV 
whole genome was digested with AvrlI and XbaI 
enzymes and ligated to generate the plasmid 
pBR325WHSdel. This plasmid has a deletion of 69 bp 
between positions 312 and 381 of WHV genome. 
Serum DNA extraction: 50 ~1 of woodchuck serum 
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were incubated with SDS and protein kinase at 65°C 
for 1 h. DNA was isolated by fenol:chloroform extrac- 
tion followed by ethanol precipitation. The resultant 
DNA pellet was dissolved in 40 ¢tl of distilled water. 
Competitive PCR:  The method used is similar to the 
one previously reported for the absolute quantitation of 
viremia in human immunodeficiency virus infection 
(27). Four reaction mixtures were analyzed: each mix- 
ture contained a constant amount of extracted serum 
DNA (5 pl) but increasing copy numbers of DNA com- 
petitor molecules (1.55x108, 1.55×107, 1.55×106 and 
1.55×105 copies/tube, respectively). These numbers of 
competitor molecules were chosen because they cover 
the range of viral DNA concentrations ormally found 
in the sera of infected woodchucks. Competitive PCR 
was done in 40 pl (final volume) containing the follow- 
ing: 5 pmol of WJL1 (TAAGCCCTGTGGTTCCT- 
ACT) and 5 pmol of WJL2 (ACCTACATAGACGCC- 
GCAAA) primers, 0.2 mM deoxynucleotides, 2.5 mM 
magnesium chloride, 20 mM Tris-HC1 (pH 8.55), 16 
mM (NH4)2SO 4 and 1.5 units of Taq polymerase (Bi- 
otaq, Bioprobe System, Paris, France). This solution 
was subjected to 35 cycles of 15 s at 95°C, 12 s at 52°C 
and 20 s at 72°C with an extension of 1 rain at 72°C. A 
Perkin Elmer GeneAmp PCR System 9600 (Norwalk, 
CT, USA) was used. Amplified cDNA was electrophor- 
esed through 2.5% agarose and visualized by UV after 
ethidium bromide staining. Gels were scanned with a 
video documentation system (GelDoc 1000, Bio-Rad 
Laboratories, Hercules, CA, USA) by positive fluor- 
escent emission on the transilluminator using the Mol- 
ecular Analyst Software (Bio-Rad Laboratories, Her- 
cules, CA, USA). Thus, the area of the peak correspond- 
ing to the wild type band sequence (WA) and that corre- 
sponding to the deleted competitor (DA) were used to 
quantify the viremia of the serum samples. DA was cor- 
rected for its lower molar ethidium bromide incorpor- 
ation as follows: DAc=DA× 1.277, where 1.277 is the 
ratio between the number of bp from the wild type band 
sequence and the number of bp from the deleted com- 
petitor. The DAc/WA ratio was calculated for each 
sample and plotted on the Y axis against he copy num- 
ber/ml of the deleted competitor. The copy number/ml 
of the wild type template was calculated from the curve 
expression DAc/WA= 1 and converted to ng/ml by di- 
viding by the factor 1.55x 107 (number of copies con- 
tained in 1 ng of WHV DNA). 
Liver biopsies 
Liver biopsies were taken by puncture with a biopsy 
needle Tru-Cut 18 Ga UTW×7.6 cm (Baxter 
Healthcare Corporation, Valencia, CA, USA) at times 
indicated in the Results section. Biopsies were fixed in 
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neutral buffered formaldehyde, mbedded in paraffin 
and sectioned at 6/~m thickness. Tissue sections were 
stained with hematoxylin and eosin, Masson's Tri- 
chrome and Periodic Acid Schiff methods. Sections 
were also examined by immunohistochemistry using a 
polyclonal rabbit antibody to recombinant WHV core 
antigen. The WHV core antigen was provided by Dr. 
Paul Cole, Georgetown University School of Medicine. 
Primary antibody was used at a 1:400 dilution, second- 
ary antibody was biotin-conjugated goat anti-rabbit 
(Biogenics, San Ramon, CA, USA) used at 1:200 di- 
lution. Peroxidase conjugated with avidin and di- 
aminobenzidine were used as the chromogen. 
Results 
In the initial experiment (Fig. 1) we tested our hypo- 
thesis by immunizing woodchucks with WHsAg in 
conjunction with FIS, a TDh peptide from sperm 
whale myoglobin well recognized by several class II re- 
strictions (7-9,28,29) or with HBs120_134, another TDh 
peptide also described as being recognized by several 
class II molecules (30). Woodchuck 310 (Fig. 1A) and 
woodchuck 90-5 (Fig. 1B) were immunized with 100 pg 
of WHsAg in conjunction with 600 pg of FIS, whereas 
woodchucks 449 and 67 (Fig. 1C and D, respectively) 
were immunized with a mixture of 100 pg of WHsAg 
and 600 pg of HBsI20_134. Fig. l shows that only wood- 
chuck 310, immunized with WHsAg in conjunction 
with FIS, elicited relevant levels of anti-WHs as well as 
of anti-FIS antibodies. The highest level of WHsAg in 
the serum was observed in this animal approximately 
3 weeks after the second immunization, whereas that 
of WHV DNA in the serum was observed after 3 weeks 
from the first immunization. These levels decreased 
later below the levels of the 2nd week. 
In woodchucks 449, 90-5 and 67 only low levels of 
anti-WHs antibodies (titers below 70) were elicited. For 
this reason, woodchucks 449 and 67, which had been 
immunized with WHsAg in conjunction with peptide 
HBs120_134, were re-immunized at week 25, but this 
time with WHsAg and FIS emulsified in incomplete 
Freund's adjuvant. As before, low levels of anti-WHs 
antibodies were observed (titers below 50). Moreover, 
re-immunization of woodchuck 90-5 with WHsAg and 
FIS did not enhance the low levels of anti-WHs anti- 
bodies previously induced. After immunization of 
woodchucks 449, 90-5 and 67 with WHsAg in conjunc- 
tion with FIS, the levels of anti-FIS antibodies were 
unmeasurable in woodchuck 67 and low in woodchuck 
90-5. Woodchuck 449 showed moderate levels of anti- 
FIS antibodies but only after 11 weeks following joint 
immunization with FIS and WHsAg. The level of 
WHV DNA in the serum of woodchucks 449, 90-5 and 
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Fig. 1. Immunization of four chronically infected woodchucks with WHsAg in conjunction with a TDh peptide. Woodchucks 
310 and 90-5 were immunized at weeks O, 5, 6 and 9 (indicated by arrows) with 100 I~g of WHsAg in conjunction with 600 
Izg of FIS. At weeks 25, 27 and 29, woodchuck 90-5 was re-immunized with 200 Izg of WHsAg and 600 Izg of FIS. Woodchucks 
449 and 67 were first immunized with 100 I, tg of WHsAg in conjunction with 600 Itg of HBs12o-134 and at a later stage with 
100 pg of WHsAg and 600 lzg of FIS. The levels of WHV DNA (ng/ml) and WHsAg (Izg/ml) in the sera, as well as the 
titers of anti-WHs, anti-FIS and anti-HBs12o~134 antibodies, are shown. In all animals, the levels of WHV DNA were 
measured by dot blot. For woodchuck 310 the sample from day 0 is not shown because it was accidentally lost. This animal 
became seriously ill and was sacrificed at week 11 after immunization. 
67 was much lower than in woodchuck 310. No clear 
changes in the level of WHsAg were seen in woodchuck 
90-5 during the 36 weeks after the first immunization. 
By contrast, in woodchucks 449 and 67 a small peak 
of WHsAg was observed, reaching the highest level at 
weeks 30 and 27, respectively, after the first immuniz- 
ation. These levels of WHsAg were similar to that ob- 
served 6 weeks after the first immunization for wood- 
chuck 310, but in woodchuck 310, WHsAg decreased 
more rapidly and to lower values. Woodchuck 310 be- 
came seriously ill and was sacrificed at week 11, as 
anti-WHs antibody levels were increasing. 
In the second set of experimental vaccinations (Fig. 
2) we tested the effect of a lower immunization dose of 
FIS and WHsAg on the outcome of immunization. 
This was decided on because in a similar experiment 
carried out in SJL mice (non-responders to HBsAg), 
we observed that lower doses of FIS elicited equal or 
better humoral responses against HBsAg (data not 
shown). Three chronically WHV-infected woodchucks 
(1D2I, 845 and 848) as well as one non-infected wood- 
chuck (1D) were immunized with WHsAg (50 ttg) in 
conjunction with FIS (200 ttg), emulsified in complete 
Freund's adjuvant as specified in Methods. To test the 
effects of FIS and WHsAg alone, we immunized chron- 
ically WHV-infected woodchuck 079 with 200 /tg of 
FIS only and woodchuck 342 with 50 ttg of WHsAg 
only. 
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Fig. 2. Immunization of woodchucks with WHsAg (50 pg) in conjunction with FIS (200 I~g) (panels A, B, C and D). 
Immunization with FIS only (200 pg) (panel E) or with WHsAg only (50 pg) (panel F). Immunizations were carried out 
at the weeks indicated by arrows. Woodchucks 1D2I, 845, 848, 079 and 342 were chronically infected with WHV, whereas 
1D was uninfected. The levels of WHV DNA (ng/ml), WHsAg (pg/ml), 7-GTP (IU/l) and bilirubin (mg/dl) in the sera, as 
well as anti-WHs and anti-FIS antibody titers, are shown. However, for woodchuck 845 the sample from day 0 is not shown 
because it was accidentally lost. In all animals, the levels of WHV DNA were measured by dot blot, except in woodchuck 
342 where competitive PCR had to be used due to the low levels of DNA in this animal. Woodchuck 1D2I died at week 24 
of fulminant hepatitis (see text). Levels of 2 IU/l of 7-GTP and 0.5 mg/dl of bilirubin are considered normal. 
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Fig. 3. (A) Liver from woodchuck 1D2! obtained before 
treatment. The histologic appearance of the liver is essen- 
tially normal There are a few mononuclear inflammatory 
cells in the portal tract (Arrow). Hepatocytes are normal 
(B) Liver from woodchuck 1D2L which died following 
treatment. The liver is characterized by massive necrosis of 
hepatocytes with areas of collapse of parenchyma, focal 
Immunization with WHsAg in conjunction with 
FIS, but not with FIS or WHsAg alone, induced de- 
tectable levels of anti-WHs antibodies (Fig. 2). The 
peak of anti-WHs antibodies was low in woodchucks 
845 and 848 (titers below 50). By contrast, woodchucks 
1D (non-infected) and 1D2I (chronically infected) 
showed substantially higher anti-WHs antibody titers. 
In all animals immunized with WHsAg in conjunction 
with FIS (Fig. 2A, B, C and D), or with FIS alone 
(Fig. 2E) anti-FIS antibodies were elicited. 
After immunization of chronically WHV-infected 
woodchucks with WHsAg in conjunction with FIS 
(Fig. 2A, B, C) or with FIS alone (Fig. 2E) a transient 
peak of WHV DNA in serum was observed. However, 
in woodchuck 342 (Fig. 2F) the levels of WHV DNA 
in the serum could not be reliably measured by dot 
blot and for this reason they were studied by competi- 
tive PCR. No important changes in the levels of WHV 
DNA were observed. The levels of WHsAg in the sera 
in all chronically infected woodchucks, with the excep- 
tion of woodchuck 848 (Fig. 2C), were also affected by 
immunization (Fig. 2A, B, E and F). These changes 
were independent of the antigen used in these immuniz- 
ation protocols. 
Fluctuations in the levels of 7-GTP were observed 
after immunization of all chronically infected wood- 
chucks in the second experiment (Fig. 2). However, 
only woodchuck 845 showed a clear peak of 7-GTP 
after the fourth immunization (Fig. 2 B). Woodchuck 
1D2I developed jaundice. Quantification of bilirubin in 
the sera of this animal showed slightly increased levels 
of this marker from the beginning of the experiment, 
reaching a level of around seven times the normal value 
at week 22 (Fig. 2 A). This animal died at week 24 of 
fulminant hepatitis (see below and Fig. 3). 
Livers from four chronically WHV-infected animals 
hemorrhage, moderate biliary hyperplas& and fine strands 
of collagen deposition extending from portal areas and cen- 
tral veins. The few remaining hepatocytes are distended by 
lipid vacuoles. These histologic hanges are compatible with 
fulminant hepatic failure. ( C) Liver from woodchuck 845 
after treatment. This liver is characterized by moderate 
mononuclear, mostly lymphocytic, infiltrates of the portal 
tracts that extend into the adjacent parenchyma. Small 
numbers of neutrophils are also present. Marked biliary 
proliferation is also evident with cholangioles extending into 
the parenchyma. Moderate parenchymal collapse with little 
fibrosis was evident in reticulum and trichrome stains. Peri- 
portal hepatocytes are distended by microvesicular and 
macrovesicular vacuoles that contain glycogen and lipid. 
Centrilobular hepatocytes are less vacuolated. 
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(1D2I, 310, 845 and 848) and one non-infected (1D), 
all of them immunized with WHsAg in conjunction 
with FIS, were examined histologically. For woodchuck 
1D2I, biopsies were obtained 4 months before immu- 
nization and 22 weeks after immunization. The initial 
biopsy was characterized by a light lymphocyte infil- 
trate of the tracts and occasional ipid-containing 
vacuoles in hepatocytes (Fig. 3A). WHV core antigen 
was present, but in low amounts in hepatocyte cyto- 
plasm. The liver obtained at death, following treatment 
of this animal, was characterized by a variety of 
lesions. The portal tracts were indistinct because of 
moderate biliary hyperplasia, mild fibrosis and a mod- 
erate lymphocyte infiltrate that bridged portal tracts 
and central veins (Fig. 3B). Significant hepatocyte ne- 
crosis was evident and remaining hepatocytes con- 
tained microvesicular and macrovesicular lipid vacu- 
oles. Widespread hemorrhage was present within the 
parenchyma. Intracanalicular bile plugs were promi- 
nent. These changes were compatible with a diagnosis 
of acute fulminant hepatitis. WHV core antigen was 
not detected. The liver from woodchuck 310, sacrificed 
at week 11 due to poor condition, was characterized 
by widespread panlobular macrovesicular lipid vacuol- 
ization of hepatocytes. Lymphocytes and occasional 
plasma cells and neutrophils were scattered throughout 
the parenchyma nd aggregates of lymphocytes were 
associated with isolated areas of spotty hepatocyte ne- 
crosis. The portal areas were moderately infiltrated 
with lymphocytes and occasional plasma cells and neu- 
trophils. The infiltrate expanded the portal tract and 
extended along the terminal branches of the portal ves- 
sels. The inflammatory infiltrates penetrated the limit- 
ing plate in multiple sites, but extended only a short 
distance into the parenchyma. Bile ducts were moder- 
ately hyperplastic. Kupffer cells appeared prominent. 
Other sections of liver were characterized by localized 
areas of infarction due to the presence of large throm- 
bus in a sublobular vein. The liver biopsy from animal 
845 obtained at week 24 after immunization showed 
prominent biliary hyperplasia nd contained a promi- 
nent inflammatory cell infiltrate of lymphocytes, neu- 
trophils and smaller number of plasma cells. These in- 
filtrates bridged portal tracts (Fig. 3C). The majority 
of hepatocytes contained microvesicular lipids. Oc- 
casionally, small aggregates of sinusoidal ining cells 
were found around necrotic hepatocytes. WHV core 
antigen was found in about 40% of hepatocytes. The 
liver from animal 848 at week 20 after immunization 
was similar, but less seriously affected. Liver from un- 
infected animal 1D, obtained 5 months before and 24 
weeks after immunization was essentially normal, 
characterized by light lymphocyte portal infiltrates and 
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TABLE 1 
In vitro IL-2 production by peripheral blood mononuclear cells fol- 
lowing stimulation with WHsAg or FIS 
Woodchuck* Immunized with Stimulation i dex (SI) 
In vitro 
stimulation 
with FIS 
(10/~g/ml) 
In vitro 
stimulation 
with WHsAg 
(100 pg/ml) 
ID ni WHsAg+ FIS 5.6 1. I 
1D2I ci WHsAg+ FIS 8.9 0.8 
845 c~ WHsAg+FIS 15.0 1.7 
848 ¢~ WHsAg+ FIS 4.7 1.1 
079 ci FIS only 109.7 NT 
342 ci WHsAg only NT 1.0 
* Non-infected (ni) and chronically infected (ci) woodchucks were im- 
munized with the antigens shown. Production of IL-2 was measured 
using the CTL-L bioassay. PBMC from these animals were re- 
stimulated with antigens as shown. Results are expressed asstimula- 
tion index (SI), which is the ratio of the mean (three determi- 
nations) counts, min-1 incorporated in the presence of antigen to 
the mean (three determinations) counts- min -1 obtained in the ab- 
sence of antigen. Only SI-3 was considered significant. 
occasional vacuolated hepatocytes in both biopsies 
(data not shown). 
To identify the antigen responsible for providing T 
cell help for antibody production, we measured IL-2 
production after in vitro stimulation of peripheral 
blood mononuclear cells (PBMC) from immunized 
woodchucks 1D, 848, 1D2I and 845, with WHsAg (100 
/zg/ml) or peptide FIS (10/tg/ml). We also studied IL- 
2 production in two control animals, immunized with 
FIS alone (woodchuck 079) or with WHsAg alone 
(woodchuck 342). Table 1 shows that re-stimulation 
with FIS, but not with WHsAg, induced significant 
levels of IL-2 (SI-3) for woodchucks 1D, 848, 1D2I 
and 845. Equivalent results were obtained after in vitro 
stimulation with 2 and 10 pg/ml of WHsAg or with 
50 pg/ml of FIS (data not shown). The PBMC from 
woodchuck 079 produced high levels of IL-2 after re- 
stimulation with FIS (SI= 119.7), whereas woodchuck 
342 did not respond to re-stimulation with WHsAg. 
These results support he hypothesis that FIS behaves 
as a TDh peptide in these woodchucks, and suggests 
that this peptide, but not WHsAg, is responsible for 
providing T cell help for antibody production. 
Discussion 
As found in human HBV carriers (1-3), insufficient T
cell help provided by viral antigens may be responsible 
for the lack of humoral response against WHsAg in 
chronic WHV carriers. As demonstrated previously by 
our laboratory, it is possible to induce antibodies 
against a peptide hapten or protein hapten by immu- 
nization with a mixture of FIS and the haptenic pep- 
tide (or protein) not covalently linked (8,9). This 
prompted us to treat chronic WHV infection by 
attempting to induce anti-WHs antibodies in nine 
chronically WHV-infected woodchucks. It was found 
that immunization with WHsAg in conjunction with a 
TDh peptide (FIS or HBs120_134) (Fig. 1 and 2), but 
not with WHsAg alone or FIS alone (Fig. 2 F and 
E, respectively), induced detectable vels of anti-WHs 
antibodies. However, only high anti-WHs antibody tit- 
ers were induced in 2/7 animals after joint immuniz- 
ation with WHsAg and FIS. The poor detection of 
anti-WHs antibodies might be related to the formation 
of immunocomplexes with circulating WHsAg in the 
serum, although no firm conclusion can be drawn be- 
cause these immunocomplexes were not measured. Sig- 
nificant levels of IL-2 (SI>-3) were observed after in 
vitro stimulation of PBMC with FIS but not with 
WHsAg (Table 1) showing that the T-cell help for anti- 
WHs antibody induction was provided by FIS and not 
by a TDh encompassed by WHsAg. We believe that 
the mechanism by which FIS helps antibody induction 
(discussed in more detail in refs. 8 and 9) may be as 
follows: FIS binds directly to empty MHC class II mol- 
ecules from B lymphocytes having recognized WHsAg 
via its surface immunoglobulin, and to other antigen- 
presenting cells. Recognition of the complex TDh- 
MHC at the surface of WHsAg-specific B lymphocytes 
by T helper lymphocytes leads to the expansion of 
WHsAg-specific B lymphocytes and to the production 
of anti-WHs antibodies. 
Among the woodchucks immunized with WHsAg 
and FIS, the highest anti-WHs antibody titer (wood- 
chuck 1D2I) was associated with a high SI in the IL- 
2 production assay (Table 1). However, the highest SI 
observed in this group was found in woodchuck 845, 
which showed a low titer of anti-WHs antibodies. This 
apparent discrepancy may be explained assuming a 
more Th2 type cytokine profile in those animals with 
the highest anti-WHs antibody responses. In future ex- 
periments we shall attempt o measure other cytokines 
such as IL-4, IL-5 and ?-IFN. 
Irrespective of the mechanism by which high anti- 
WHs antibodies were elicited, it is interesting to note 
that those animals that were immunized with WHsAg 
and FIS, and from which liver samples were taken (310, 
1D2I, 845 and 848), showed an evident hepatic in- 
flammation (Fig. 3). Greater liver damage was ob- 
served in animals with higher anti-WHs antibody tit- 
ers. Indeed, the two animals that died (1D2I and 310) 
had anti-WHs antibody titers that were higher than in 
any of the other immunized chronically infected wood- 
chucks. Also, in these two animals, after a transient 
Therapeutic vaccination against WHV 
peak, the WHV DNA decreased below the basal levels 
at the time of death (Table 1). It is likely that the ful- 
minant hepatitis that followed immunization of wood- 
chuck 1D2I may be related to the induction of anti- 
WHs antibodies, which in turn, could be responsible 
for the induction of a strong, antibody-dependent, cell- 
mediated cytotoxicity. However, we can not discard the 
possibility of a direct T cell cytotoxicity induced by 
WHsAg through the T cell help provided by FIS. The 
peaks of WHV DNA and WHsAg in the sera that fol- 
lowed immunization might be a consequence of the in- 
duced cytotoxicity. However, since this peak was also 
observed following immunization with FIS alone 
(woodchuck 079, Fig. 2 E), it could be speculated that 
it might be due to a transiently enhanced viral repli- 
cation in infected cells (B and T cells) following a pro- 
liferation stimulus provided by FIS. This situation may 
resemble the in vitro production of WHV by E. coli 
lipopolysaccharide-stimulated PBMC (31). 
As mentioned earlier, induction of high anti-WHs 
antibody titers was associated with severe liver dam- 
age, suggesting a strong activation of the immune sys- 
tem. A less intense activation may take place when 
these antibody titers are lower, for instance in wood- 
chuck 845 (Fig. 2 B), for which a flare-up of 7-GTP 
is clearly observed after joint immunization with FIS 
and WHsAg. This flare-up of y-GTP may resemble 
the episode of ALT observed by Wen et al. (5) and 
Pol et al. (6) in vaccinated chronically infected pa- 
tients showing a decrease or clearance of HBV DNA 
in their sera. 
Our results indicate that antibodies against WHsAg 
can be induced in chronic WHV infection, by joint im- 
munization with surface antigen and an adequate TDh 
peptide like FIS. As mentioned in the introduction, 
therapeutic vaccination of chronic HBV carriers has 
been attempted before (4-6). An alternative to this ap- 
proach was tested in the woodchuck using complete 
recombinant WHV core protein (13). However, only 
one out of six woodchucks eliminated WHV after vac- 
cination with recombinant WHV core protein. These 
strategies differ from the one reported here, mainly in 
that the T cell help must necessarily be induced via 
TDh peptide sequences that are an integral part of the 
viral antigens, while in our study T cell help is induced 
by co-immunization with a conveniently chosen TDh 
peptide not covalently linked to the surface antigen. 
We believe that our strategy may have the advantage 
over other methods of immunization (4-6) of providing 
help via a TDh for which tolerance has not been in- 
duced, as might be the case for some or all the TDh 
from viral antigens. Also, our immunization protocol 
uses a great excess of TDh, which may favor direct 
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binding to empty MHC class II molecules from surface 
antigen-specific B lymphocytes. This protocol may po- 
tentiate the induction of anti-surface antibodies more 
efficiently than immunization with vaccine alone, 
where no antibodies were detected (4-6). Unfortu- 
nately, as seen in woodchuck 1D2I, this procedure of 
inducing anti-WHs antibodies may lead to significant 
hepatic injury, including fulminant hepatitis. Thus, our 
approach needs to be modulated in such a way that 
the rate of lysis of infected hepatocytes i  lower than 
hepatocyte regeneration. 
To modulate the immune response, co-immunization 
with an adequate TDh peptide (as in the present 
study), could be envisaged. Another alternative might 
be to administer cytokines or antibodies against cyto- 
kines that, as in the case of murine leishmaniasis, 
might alter the pattern of the immune response (32,33). 
Along a similar line of reasoning, Milich et al. (34) 
have suggested that a goal of immunomodulatory ther- 
apy in patients with chronic HBV infection might be 
to shift the balance of T cells from Th2 to Thl  pre- 
dominance. Our joint immunization procedure might 
be conducted in such a way as to choose a TDh peptide 
to induce the desired pattern of Thl /Th2 cell response. 
This could be done by selecting peptides that elicit 
mainly Thl  or Th2 responses (35). This may bypass 
nonresponsiveness to TDh peptides from viral anti- 
gens, and offer the possibility of a tailor-made immu- 
nization according to the HLA-DR of the chronic pa- 
tient. A more efficient approach would be to select a 
promiscuous TDh peptide covering a greater number 
of HLA-DR alleles. 
Another strategy to treat chronically infected pa- 
tients might be to induce a cytotoxic response using 
peptide constructs containing a helper and a cytotoxic 
cell determinant covalently linked (10,11,36,37). Simi- 
lar peptide constructs of the core protein have been 
tested by Vitiello et al. (38) to try to induce cytotoxic 
responses in human volunteers. 
Vaccination of chronically HBV-infected patients 
with vaccines containing the surface antigen have been 
reported to be safe and without side-effects (4-6). In 
contrast, although ablation of persistent hepatitis B, 
due to adoptive transfer of specific immunity against 
HBV, has been reported after bone marrow transplan- 
tation (39), this procedure may also lead to fatal hepa- 
titis B reactivation (40). This result, in conjunction 
with our experiments in the woodchuck reported here, 
suggests that an enhancement of the immune response 
in chronic carriers could have deleterious consequences 
for liver function. Caution should be used in human 
immunization trials to avoid the possibility of similar 
problems. 
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